Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular characterization of genomic breakpoints of ALK rearrangements in non‐small cell lung cancer

24 Nov 2022

Abstract excerpt

ALK rearrangement is called the 'diamond mutation' in non-small cell lung cancer (NSCLC). Accurately identifying patients who are candidates for ALK inhibitors is a key step in making clinical treatment decisions. In this study, a total of 783 ALK rearrangement-positive NSCLC cases were identified by DNA-based next-generation sequencing (NGS), including 731 patients with EML4-ALK and 52 patients with other ALK...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36423218
DOI: 10.1002/1878-0261.13348

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular characterization of genomic breakpoints of ALK rearrangements in non‐small cell lung cancerPMID 36423218Read ↗

Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancersSemantic proximity Read ↗

Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancersSemantic proximity Read ↗

Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancerSemantic proximity Read ↗

Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLCSemantic proximity Read ↗

Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.Semantic proximity Read ↗

ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancerSemantic proximity Read ↗

Reliability analysis of exonic-breakpoint fusions identified by DNA sequencing for predicting the efficacy of targeted therapy in non-small cell lung cancerSemantic proximity Read ↗

Detection of multiple types of cancer driver mutations using targeted RNA sequencing in non-small cell lung cancer.Semantic proximity Read ↗

Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications.Semantic proximity Read ↗

Gene rearrangement detection by next-generation sequencing in patients with non-small cell lung carcinoma.Semantic proximity Read ↗

Detection of Multiple Types of Cancer Driver Mutations Using Targeted RNA Sequencing in NSCLCSemantic proximity Read ↗

Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.